These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. Abounader R; Lal B; Luddy C; Koe G; Davidson B; Rosen EM; Laterra J FASEB J; 2002 Jan; 16(1):108-10. PubMed ID: 11729097 [TBL] [Abstract][Full Text] [Related]
3. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Lamszus K; Laterra J; Westphal M; Rosen EM Int J Dev Neurosci; 1999; 17(5-6):517-30. PubMed ID: 10571413 [TBL] [Abstract][Full Text] [Related]
4. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398 [TBL] [Abstract][Full Text] [Related]
5. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review). Moriyama T; Kataoka H; Koono M; Wakisaka S Int J Mol Med; 1999 May; 3(5):531-6. PubMed ID: 10202187 [TBL] [Abstract][Full Text] [Related]
6. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431 [TBL] [Abstract][Full Text] [Related]
7. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Hu B; Guo P; Bar-Joseph I; Imanishi Y; Jarzynka MJ; Bogler O; Mikkelsen T; Hirose T; Nishikawa R; Cheng SY Oncogene; 2007 Aug; 26(38):5577-86. PubMed ID: 17369861 [TBL] [Abstract][Full Text] [Related]
9. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060 [TBL] [Abstract][Full Text] [Related]
10. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Martin TA; Parr C; Davies G; Watkins G; Lane J; Matsumoto K; Nakamura T; Mansel RE; Jiang WG Carcinogenesis; 2003 Aug; 24(8):1317-23. PubMed ID: 12807719 [TBL] [Abstract][Full Text] [Related]
11. NK4 gene therapy targeting HGF-Met and angiogenesis. Matsumoto K; Nakamura T Front Biosci; 2008 Jan; 13():1943-51. PubMed ID: 17981681 [TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Zhang YW; Su Y; Volpert OV; Vande Woude GF Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12718-23. PubMed ID: 14555767 [TBL] [Abstract][Full Text] [Related]
13. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway. Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476 [TBL] [Abstract][Full Text] [Related]
14. HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics. Mizuno S; Nakamura T Int J Mol Sci; 2013 Jan; 14(1):888-919. PubMed ID: 23296269 [TBL] [Abstract][Full Text] [Related]
15. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Davies G; Mason MD; Martin TA; Parr C; Watkins G; Lane J; Matsumoto K; Nakamura T; Jiang WG Int J Cancer; 2003 Sep; 106(3):348-54. PubMed ID: 12845672 [TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. Tolnay E; Kuhnen C; Wiethege T; König JE; Voss B; Müller KM J Cancer Res Clin Oncol; 1998; 124(6):291-6. PubMed ID: 9692834 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Gao CF; Xie Q; Zhang YW; Su Y; Zhao P; Cao B; Furge K; Sun J; Rex K; Osgood T; Coxon A; Burgess TL; Vande Woude GF Mol Cancer Ther; 2009 Oct; 8(10):2803-10. PubMed ID: 19825800 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Brockmann MA; Papadimitriou A; Brandt M; Fillbrandt R; Westphal M; Lamszus K Clin Cancer Res; 2003 Oct; 9(12):4578-85. PubMed ID: 14555533 [TBL] [Abstract][Full Text] [Related]
20. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review). To CT; Tsao MS Oncol Rep; 1998; 5(5):1013-24. PubMed ID: 9683803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]